Global Surveillance for Antituberculosis-Drug Resistance, 1994-1997

New England Journal of Medicine

Volumn 338, Issue 23, 1998, Pages 1641-1649

  Pablos Méndez, Ariel ^a,b,i   Raviglione, Mario C ^a   Laszlo, Adalbert ^c,d   Binkin, Nancy ^e   Rieder, Hans L ^c   Bustreo, Flavia ^a   Cohn, David L ^f   Lambregts Van Weezenbeek, Catherina S B ^g   Kim, Sang Jae ^h   Chaulet, Pierre ^a   Nunn, Paul ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d LAB CENTRE FOR DISEASE CONTROL   (Canada)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^h Korean Institute of Tuberculosis   (South Korea)

ⁱ Columbia Coll of Phys and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARGENTINA; ARTICLE; ASIA; CLINICAL PROTOCOL; DOMINICAN REPUBLIC; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; USSR; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; ETHAMBUTOL; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; PREVALENCE; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 0042794841     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199806043382301     Document Type: Article

References (58)

1. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
2. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. BMJ 1948;2:1009-15.
3. Hong Kong Government Tuberculosis Service/British Medical Research Council. Drug-resistance in patients with pulmonary tuberculosis presenting at chest clinics in Hong Kong. Tubercle 1964;45:77-95.
4. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703.
5. Public Health Service Cooperative Investigation. Prevalence of drug resistance in previously untreated patients. Am Rev Respir Dis 1964;89:327-36.
6. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-6.
7. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44.
8. Dooley SW, Jarvis WR, Martone WJ, Snider DE Jr. Multidrug-resistant tuberculosis. Ann Intern Med 1992;117:257-9.
9. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
10. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993;168: 1052-5.
11. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991;40:585-91.
12. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328: 521-6. [Erratum, N Engl J Med 1993;329:148.]
13. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resisrant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-83.
14. Monno L, Angarano G, Carbonara S, et al. Emergence of drug-resistant Mycobacterium tuberculosis in HIV-infected patients. Lancet 1991;337:852.
15. Bouvet E. Transmission nosocomiale de tuberculose multirésistante parmi les patients infectés par le VIH: en France, à Paris. Bull Epidemiol Hebd 1991;45:196-7.
16. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep 1996;45:330-3.
17. Cohn ML, Middlebrook G, Russell WF Jr. Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro. J Clin Invest 1959;38:1349-55.
18. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993;144:104-10.
19. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
20. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-30.
21. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-35.
22. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996;276:1223-8.
23. Coninx R, Pfyffer G, Mathieu C, et al. Multidrug resistant tuberculosis in Azerbaijan. Int J Tuberc Lung Dis 1997;1:Suppl 1:S43. abstract.
24. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-8.
25. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997;24:Suppl 1:S121-S130.
26. Pablos-Méndez A, Laszlo A, Bustreo F, et al. Anti-tuberculosis drug resistance in the world. Geneva: WHO Global Tuberculosis Programme, 1997. (Publication no. WHO/GTB/97.229.)
27. WHO/IUATLD Global Working Group on Antituberculosis Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Health Organization, 1997. (Publication no. WHO/TB/96.216.)
28. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
29. Tuberculosis programme: framework tor effective tuberculosis control. Geneva: World Health Organization, 1994. (Publication no. WHO/TB/ 94.179.)
30. World Health Organization. Standardization of methods for conducting microbic sensitivity tests. WHO Tech Rep Ser 1961;210:3-24.
31. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
32. Manual of bacteriology of tuberculosis. Washington, D.C.: World Health Organization/Pan American Health Organization, 1983.
33. Siddiqi SH. Bactec TB system: product and procedure manual. Towson, Md.: Becton Dickinson, 1989.
34. Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997;1:231-8.
35. Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. Lancet 1997;350:624-9.
36. Morcillo N, Alito A, Romano MI, et al. Multidrug resistant tuberculosis outbreak in Buenos Aires: DNA fingerprinting analysis of isolates. Medicina (B Aires) 1996;56:45-7.
37. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220-6.
38. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull World Health Organ 1993; 71:297-306.
39. Lambregts-van Weezenbeek CSB. Drug-resistant tuberculosis. Eur Respir Monogr 1997;2(4):298-326.
40. Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A. Tuberculosis trends in eastern Europe and the former USSR. Tuberc Lung Dis 1994;75:400-16.
41. Murray C, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65(1):6-24.
42. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996;347:358-62.
43. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997;1:302-8.
44. Kim SJ, Hong YP. Drug resistance of Mycobacterium tuberculosis in Korea. Tuberc Lung Dis 1992;73:219-24.
45. Styblo K, Dankova D, Drapela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia: report for the first 4 years of the study (1961-64). Bull World Health Organ 1967;37: 819-74.
46. Boulahbal F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bull Int Union Tuberc Lung Dis 1989;64(3):23-5.
47. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945-51.
48. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City: history, implementation, results, and challenges. Clin Chest Med 1997;18:135-48.
49. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995;333:229-33.
50. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
51. Barnes PF. The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis 1987;136:325-8.
52. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 1994. Thorax 1994;49:1193-200.
53. Kennedy N, Billington O, Mackay A, Gillespie SH, Bannister B. Reemergence of tuberculosis. BMJ 1993;306:514.
54. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 1995;332:1071-6.
55. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tuberc Lung Dis 1995;76:487-92.
56. Chaulet P. Tuberculose et transition épidémiologique: le cas de l'Algérie. Ann Inst Pasteur 1993;4:181-7.
57. Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: World Health Organization, 1997. (Publication no. WHO/TB/97.220.)
58. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997. (Publication no. WHO/GTB/96.210.)